Novartis

Novartis Campus, Basel, Baselstadt, 4002, CH

1996-01-01

10001+

$1 Billion

View Employees in Novartis
Real-Time AI Research
0 search queries left
FlashIntel GPT
Hello! I'm FlashIntel GPT, your personal AI search assistant. Feel free to ask me anything about Novartis, and I'll do my best to assist you.
You

Tell me more about Novartis?

FlashIntel GPT
Novartis is committed to discovering and developing breakthrough treatments and finding new ways to deliver them to as many people as possible. They are committed to building an Inspired, Curious, and Unbossed culture, and have recently announced the potential of remibrutinib as an oral treatment for chronic spontaneous urticaria and Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients
Want to view all employees of this company? Start for free trial.
Research Details
News &Insights
Key People

view 77,331 associated members

Novartis In Short

Providence Health & Services, founded in 1859, is a global healthcare company based in Renton, Washington, United States, with 20663 employees. Specializing in hospitals and health care, the company offers a wide range of services including cancer, heart & vascular neurosciences, orthopedics, primary care, pediatrics, maternal, urgent care, and more. Providence's mission is to help organizations and programs create lasting change and improve health and well-being at the community level.

Company Description of Novartis

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Novartis Campus, Basel, Baselstadt, 4002, CH

77331

Show More

What does Novartis offer?

Novartis is committed to discovering and developing breakthrough treatments and finding new ways to deliver them to as many people as possible. They are committed to building an Inspired, Curious, and Unbossed culture, and have recently announced the potential of remibrutinib as an oral treatment for chronic spontaneous urticaria and Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients